+62.2%
GSK vs ROIV
+200.3%
-138.1%
-28.5%
Performance
Returns, benchmark comparison, and relative performance.
Performance by timeframe
Returns for 3y.
| Period | Portfolio | ROIV | Excess | Alpha |
|---|---|---|---|---|
| 1D | -1.9% | +1.5% | -3.4% | -2.1% |
| 7D | -1.8% | +0.6% | -2.5% | -1.9% |
| 30D | -2.2% | +1.0% | -3.1% | -2.3% |
| 3M | -1.8% | +18.3% | -20.1% | -3.7% |
| 6M | -10.6% | +18.3% | -28.9% | -12.6% |
| YTD | +4.4% | +61.0% | -56.5% | -1.2% |
| 1Y | +30.4% | +177.9% | -147.5% | +16.7% |
| All | +62.2% | +200.3% | -138.1% | +42.8% |
Cumulative growth
Daily Returns
Daily percentage return beside ROIV.
Daily Out/Under-Performance
Portfolio return minus ROIV return. Positive bars indicate outperformance.
Daily Alpha
Portfolio daily return minus β × ROIV return. Early observations use the first valid beta; later observations use the trailing beta estimated for each date.
Cumulative Out/Under-Performance
Relative wealth over 3y: compounded portfolio wealth divided by compounded ROIV wealth, less one. Both series rebase at the selected span's start.
Cumulative Alpha
Compounded beta-adjusted residual returns apply the first valid beta to early observations, then the trailing beta ending on each date.
Updating return analytics…
3y analysis · Full analysis span regression · 6 months rolling